|4.30|| 0.00 / 0.00%|
Invivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. Its platform technologies focus on minimizing tissue damage sustained following acute injury and promoting neural plasticity of the spared healthy tissue, which may result in full or partial functional recovery. The company intends to leverage its primary platform technology to develop and commercialize three products: a biocompatible polymer scaffolding device to treat acute spinal cord injuries; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute spinal cord injuries and a biocompatible polymer scaffolding device seeded with autologous human neural stem cells to treat acute and chronic spinal cord injuries. Its additional applications of platform technologies include the potential treatment for, spinal cord injury following tumor removal, peripheral nerve damage, and postsurgical treatment of any transected nerve. Invivo Therapeutics Holdings was founded by Joseph P. Vacanti, Frank M. Reynolds and Robert Langer on November 28, 2005 and is headquartered in Cambridge, MA.
|Mark D. Perrin||Chairman & Chief Executive Officer|
|William D'Agostino||Senior Vice President-Operations|
|Melanie Morel-Ferris||Chief Financial & Accounting Officer|
|Kristin Neff||VP-Clinical Operations & Project Management|
|Thomas R. Ulich||Chief Scientific Officer|